Myasthenia Gravis Trial, Recruiting (NCT04202341)

Myasthenia Gravis Trial, Recruiting NCT04202341 Sponsor: Alexion Pharmaceuticals, Inc. Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT04202341 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a form of Myasthenia Gravis called generalized Myasthenia Gravis (gMG) and are currently being treated with, or have previously been treated with, an Alexion C5 inhibitor therapy (such as Soliris or Ultomiris), even if you have since stopped that treatment.
You are able to understand and agree to take part in the study and follow its requirements by signing a consent form.
You have past medical records related to your Myasthenia Gravis available, such as previous symptom scores or disease severity classifications (confirm with trial site).

Who may not be able to join:

You are currently taking part in another Alexion-sponsored clinical trial that is testing a treatment for generalized Myasthenia Gravis.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-855-752-2356

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04202341

Sponsor: Alexion Pharmaceuticals, Inc.

Phase: Not Applicable

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 1-855-752-2356

More information: https://clinicaltrials.gov/study/NCT04202341

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a form of Myasthenia Gravis called generalized Myasthenia Gravis (gMG) and are currently being treated with, or have previously been treated with, an Alexion C5 inhibitor therapy (such as Soliris or Ultomiris), even if you have since stopped that treatment.
You are able to understand and agree to take part in the study and follow its requirements by signing a consent form.
You have past medical records related to your Myasthenia Gravis available, such as previous symptom scores or disease severity classifications (confirm with trial site).

Who may not be able to join:

You are currently taking part in another Alexion-sponsored clinical trial that is testing a treatment for generalized Myasthenia Gravis.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Alexion Pharmaceuticals, Inc.

Registry

ClinicalTrials.gov

Start date

2 December 2019

Est. completion

1 October 2029

Where this trial is recruiting

🇦🇹 Austria 🇨🇦 Canada 🇨🇳 China 🇩🇪 Germany 🇮🇹 Italy 🇸🇦 Saudi Arabia 🇺🇸 United States

Primary endpoints

Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov